transdermal bpc 157 bpc-157 patch PREMIER PATCH THERAPY™ bpc 157 transdermal patches NAD+

Key facts: First studied by researchers at the University of Zagreb (Croatia) in the early 1990s Over 100 peer-reviewed studies published since then (Kang et al., 2021) Administered via subcutaneous injection (most common), intramuscular injection, or orally Typical research dosages: 200-800 mcg per day Classification: Research peptide, not approved by the FDA for human use How it works (simplified): BPC-157 appears to promote healing by improving blood flow to damaged tissue, reducing inflammation, and supporting the body's natural repair processes

Flat $30 shipping.

As individuals seek innovative approaches to health and wellness, it is essential to approach peptide supplementation with caution and under the guidance of Qaly providers